UK government rules out purchase of Evusheld over lack of data

摘要

The UK government has said it will not purchase any doses of the COV1D-19 monoclonal antibody cocktail Evusheld (tixagevimab + cilgavimab; AstraZeneca) owing to a lack of data on the level of protection it offers. Evusheld is a combination of two monoclonal antibodies -tixagevimab and cilgavimab — and works by binding to the spike protein of the SARS-CoV-2 virus, preventing it from attaching and entering human cells.